Since 2004, intravitreal antivascular endothelial growth factor (VEGF) therapy has become the standard treatment for neovascular age-related degeneration (AMD) and has radically changed the management and the clinical prognosis of this disease. This evidence concerns the gene VEGFA and age-related macular degeneration.